REGENXBIO Inc. $RGNX Shares Acquired by AlphaQuest LLC

Key Points

• AlphaQuest LLC increased its stake in REGENXBIO Inc. by 657.7% in the first quarter, owning 60,309 shares worth $431,000 after acquiring an additional 52,350 shares.
• Several hedge funds have also acquired shares in REGENXBIO, with institutional investors now owning 88.08% of the company's stock.
• Analyst ratings vary, with a consensus average rating of "Moderate Buy" and a price target of $28.38, despite some analysts issuing ratings as low as "strong sell."

AlphaQuest LLC increased its position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 657.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 60,309 shares of the biotechnology company's stock after buying an additional 52,350 shares during the quarter. AlphaQuest LLC owned about 0.12% of REGENXBIO worth $431,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Janney Montgomery Scott LLC purchased a new position in shares of REGENXBIO in the 1st quarter worth $484,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of REGENXBIO in the 1st quarter worth $123,000. Price T Rowe Associates Inc. MD raised its position in shares of REGENXBIO by 9.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock worth $185,000 after buying an additional 1,982 shares during the period. BNP Paribas Financial Markets raised its position in shares of REGENXBIO by 370.1% in the 4th quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock worth $743,000 after buying an additional 75,652 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of REGENXBIO by 34.0% in the 4th quarter. Wells Fargo & Company MN now owns 48,437 shares of the biotechnology company's stock worth $374,000 after buying an additional 12,285 shares during the period. 88.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on RGNX shares. Barclays cut their target price on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research report on Friday, August 8th. Royal Bank Of Canada cut their price objective on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Wall Street Zen lowered REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. HC Wainwright reissued a "buy" rating and issued a $34.00 price objective on shares of REGENXBIO in a research report on Tuesday, August 19th. Finally, Chardan Capital reissued a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Friday, August 8th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $28.38.

REGENXBIO Stock Performance

Shares of NASDAQ RGNX traded down $0.08 during midday trading on Monday, reaching $8.93. 467,067 shares of the company's stock were exchanged, compared to its average volume of 690,520. REGENXBIO Inc. has a 52-week low of $5.03 and a 52-week high of $13.48. The stock has a market capitalization of $451.05 million, a PE ratio of -2.60 and a beta of 1.17. The business's fifty day moving average price is $8.55 and its two-hundred day moving average price is $8.11.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The business had revenue of $21.36 million for the quarter, compared to analysts' expectations of $40.87 million. Analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.